NCT03737474View on ClinicalTrials.gov

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

March 17, 2021

Study Completion Date

April 13, 2021

Conditions
Major Depressive Disorder
Interventions
DRUG

Brexpiprazole

2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily

Trial Locations (1)

Unknown

Nanko-kokorono clinic, Shirakawa

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY